BEST ADD-ON THERAPY GIVING EFFECTIVE RESPONSES (BADGER)

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 吸入皮质类固醇（ICS）单一疗法治疗儿童轻度至中度持续性哮喘已被证明对大多数儿童有益。 研究哮喘治疗方案的下一步自然是当 ICS 单一疗法不足以令人满意地控制哮喘时，确定 ICS 的最佳附加药物（增加 ICS、LABA 或 LTRA）。 BADGER（即给出有效反应的最佳附加疗法）将回答有关 180 名儿童（每个临床中心 36 名）的最佳附加药物的问题，这些儿童有轻度至中度哮喘病史，且低剂量 ICS 未完全控制病情。 该研究设计是三重交叉，每个孩子都接受每种附加药物。 主要结局是基于哮喘恶化、哮喘控制天数和一秒用力呼气量变化（肺功能测试）的治疗反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Monotherapy with inhaled corticosteroid (ICS) in mild to moderate persistent asthma in children has been shown to be beneficial in most children. The natural next step in studying asthma therapy options is determining the optimal add-on medication (increasing ICS, LABA or LTRA) to ICS when monotherapy with ICS at that dose is inadequate to control asthma satisfactorily. BADGER, or Best Add-on Therapy Giving Effective Responses, will answer the question about best add-on medication in 180 children (36 per clinical center) who have a history of mild to moderate asthma and are not completely controlled on low dose ICS. The study design is a triple cross over with each child receiving each add-on medication. The primary outcomes will be treatment response based on asthma exacerbation, asthma control days, and change in forced expiratory volume in one second (lung function testing).